Central Nervous System News and Research

RSS

Alcohol consumption during pregnancy has detrimental effects on fetal central nervous development

Maternal alcohol consumption during pregnancy has detrimental effects on fetal central nervous system development. Maternal alcohol consumption prior to and during pregnancy significantly affects cognitive functions in offspring, which may be related to changes in cyclin-dependent kinase 5 because it is associated with modulation of synaptic plasticity and impaired learning and memory.

20 Jul 2013

Study supports topiramate as promising medication to treat addiction

The drug topiramate, typically used to treat epilepsy and more recently weight loss, may also help people addicted to both cocaine and alcohol use less cocaine, particularly heavy users, researchers in the department of Psychiatry at Penn Medicine report in a new study published in Drug and Alcohol Dependence.

19 Jul 2013

FDA grants orphan drug designation to ARMAGEN's AGT-182 for treatment of Hunter syndrome

ARMAGEN announced today that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product AGT-182 for the treatment of mucopolysaccharidosis type II (also known as Hunter syndrome or MPS II).

19 Jul 2013

Weill Cornell reports new findings from IVIG Phase 3 trial in Alzheimer's disease at AAIC 2013

Weill Cornell Medical College neurologist Dr. Norman Relkin reported new findings today from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease at the Alzheimer's Association International Conference in Boston, Mass.

16 Jul 2013

UAB researchers study link between sleep and pain among patients with knee osteoarthritis

Researchers at the University of Alabama at Birmingham want to know more about the relationship between sleep and pain.

16 Jul 2013

Stem-cell therapy for treatment of stroke has benefits as well as risk: Research

While stem-cell therapy offers great promise for the treatment of stroke, much research remains to be done to show its long-term effectiveness and to understand the potential for dangerous side effects.

12 Jul 2013

IDSA and ASM collaborate to guide the best use of lab tests for diagnosis of infectious diseases

A new guide developed by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) will help physicians appropriately and accurately use laboratory tests for the diagnosis of infectious diseases. Laboratory test results drive approximately two-thirds of physicians' medical decisions.

11 Jul 2013

VBL Therapeutics publishes VB-201 pre-clinical data in journal of Atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, announced today the publication of pre-clinical data for VB-201 in the journal of Atherosclerosis.

8 Jul 2013

Findings uncover epigenomic modification that occurs during brain formation

Changes in the epigenome, including chemical modifications of DNA, can act as an extra layer of information in the genome, and are thought to play a role in learning and memory, as well as in age-related cognitive decline.

5 Jul 2013

Study shows possible biological cause of narcolepsy

In 2000, researchers at the UCLA Center for Sleep Research published findings showing that people suffering from narcolepsy, a disorder characterized by uncontrollable periods of deep sleep, had 90 percent fewer neurons containing the neuropeptide hypocretin in their brains than healthy people.

4 Jul 2013

Research: Change in functional state, structure of spinal cord and brain occur within 40 days of injury

A spinal cord injury changes the functional state and structure of the spinal cord and the brain. For example, the patients' ability to walk or move their hands can become restricted. How quickly such degenerative changes develop, however, has remained a mystery until now.

3 Jul 2013

Olfactory ensheathing cells treatment improves neurological function in SCI patients: Study

A team of researchers in Poland who treated three of six paraplegics with spinal cord injury using transplanted olfactory ensheathing cells found that the three treated patients showed neurological improvement and no adverse effects while the three control patients who did not receive transplants saw no improvement.

29 Jun 2013

New study explains how the brain maintains zinc balance during embryonic development

A new study helps explain how parts of the brain maintain their delicate balance of zinc, an element required in minute but crucial doses, particularly during embryonic development.

27 Jun 2013

Researchers study possible alternative medications to treat cancer-related pain

Researchers at the Brain and Spine Institute at John Theurer Cancer Center at HackensackUMC, one of the nation's 50 best hospitals for cancer, are studying a possible alternative to side effect-ridden opioid-based medications to treat cancer-related pain.

27 Jun 2013

Highland Therapeutics subsidiary reports positive HLD-200 Phase-1 results in ADHD patients

Highland Therapeutics, Inc., a specialty pharmaceutical company based in the MaRS Discovery District in Toronto, today announced that its wholly owned subsidiary has generated positive Phase-1 results for HLD-200 - a novel formulation of methylphenidate being developed to treat the symptoms associated with Attention-Deficit/Hyperactivity Disorder.

25 Jun 2013

Penn researchers find ALS disease progresses in a stepwise, sequential pattern

The motor neuron disease Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, progresses in a stepwise, sequential pattern which can be classified into four distinct stages, report pathologists with the Perelman School of Medicine at the University of Pennsylvania in the Annals of Neurology.

20 Jun 2013

Safinamide improves responder rates in fluctuating Parkinson's patients in Phase III study

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., a pharmaceutical company strongly committed to the respiratory, primary care and CNS therapeutic areas, presented results from SETTLE Phase III study with safinamide at the 17th International Congress of Parkinson's disease and Movement Disorders, taking place from June 16 to 20, 2013, at the Sydney Convention and Exhibition Centre, Sydney, Australia.

19 Jun 2013

Researchers identify new virus in patients with severe brain infections

Researchers have identified a new virus in patients with severe brain infections in Vietnam. Further research is needed to determine whether the virus is responsible for the symptoms of disease.

18 Jun 2013

Patients with central nervous system infections may suffer from the effects of CyCV-VN virus: Study

Patients in Vietnam and other locations with central nervous system infections may well be suffering from the effects of a newly discovered virus, according to a study to be published in mBio-, the online open-access journal of the American Society for Microbiology.